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Motion predictionBackground and purpose: The latency of a multileaf collimator (MLC) tracking system used to overcome
respiratory motion causes misalignment of the treatment beam with respect to the gross tumour volume,
which may result in reduced target coverage. This study investigates the magnitude of this effect.
Material and methods: Simulated superior–inferior breathing motion was used to construct histograms of
isocentre offset with respect to the gross tumour volume (GTV) for a variety of tracking latencies. Dose
distributions for conformal volumetric modulated arc therapy (VMAT) arcs were then calculated at a
range of offsets and summed according to these displacement histograms. The results were verified by
delivering the plans to a Delta4 phantom on a motion platform.
Results: In the absence of an internal target margin, a tracking latency of 150 ms reduces the GTV D95% by
approximately 2%. With a margin of 2 mm, the same drop in dose occurs for a tracking latency of 450 ms.
Lung V13Gy is unaffected by a range of latencies. These results are supported by the phantom measure-
ments.
Conclusions: Assuming that internal motion can be modelled by a rigid translation of the patient, MLC
tracking of conformal VMAT can be effectively accomplished in the absence of an internal target margin
for substantial breathing motion (4 s period and 20 mm peak–peak amplitude) so long as the system
latency is less than 150 ms.
 2015 The Royal Marsden NHS Foundation Trust. Published by Elsevier Ireland Ltd. Radiotherapy and
Oncology 117 (2015) 491–495 This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Multileaf collimator (MLC) tracking is emerging as an important
method of minimising normal tissue doses in the presence of res-
piratory motion [1,2]. Instead of adding an internal target margin
to the clinical target volume (CTV) to create an internal target vol-
ume (ITV) which encompasses the tumour at most of its cyclical
positions, the leaves of the MLC are used to follow the target,
thereby enabling the ITV to be small or absent and consequently
sparing adjacent normal tissues [3].
However, MLC tracking is rarely perfect. There is an inherent
delay in the detection of the target position, the processing of this
information into appropriate MLC leaf positions and the subse-
quent movement of the MLC leaves to the desired updated position
[4,5]. The total delay due to all of these factors is referred to as the
system latency [6]. Typical values reported in the literature vary
from 50 ms to 500 ms for different tracking systems [6–10]. Ifthe respiratory motion is reasonably repetitive, motion prediction
algorithms can be used to predict the position of the tumour at
the end of the latency period and drive the MLC directly to where
the tumour is expected to be [10]. In this case, any remaining
latency is referred to as residual system latency.
The impact of system latency is to introduce an offset between
the position of the CTV and the position of the treatment beam.
This is expected to reduce the CTV coverage and increase the nor-
mal tissue dose. However, it is currently unclear exactly what the
dosimetric impact of the latency is. This study therefore aims to
quantify as accurately as possible the impact of various system
latencies on the coverage of the CTV and on the surrounding nor-
mal tissue, taking into account the beam characteristics and the
variation in density of the patient around the gross tumour volume
(GTV). The case of stereotactic ablative body radiotherapy (SABR)
for lung is considered [11], as this is a likely scenario for the use
of MLC tracking. The study consists of two parts: firstly calculating
the expected target coverage based on a treatment planning study,
thereby allowing acceptable latency to be defined, and secondly,
the verification of the results by delivering the treatment plans
492 VMAT lung tracking latencyto a moving phantom. The study also evaluates what tracking ITV
marginmight be necessary to overcome any residual system latency.
Materials and methods
Treatment plans
Five typical SABR lung patients were retrospectively studied,
with three tumours located in the upper lobes and two in the lower
lobes close to the diaphragm, and with a GTV ranging from
12.8 cm3 to 48.5 cm3. CT scans were acquired in breath hold using
Active Breathing Coordinator (ABC) (Elekta AB, Stockholm,
Sweden), with a slice thickness and spacing of 2 mm. The gross
tumour was delineated and the CTV was taken to be equal to the
GTV, in accord with normal practice for this type of treatment
[11]. It was then assumed that the static CT scan with an isocentre
at the geometric centre of the GTV represented a perfectly tracked
tumour with zero system latency. To evaluate what margin might
be needed to overcome the effect of latency, a series of tracking
ITVs were created, consisting of the GTV plus a margin of between
0 mm and 5 mm in the superior–inferior direction and 0 mm in the
other directions. The PTV was equal to the tracking ITV as no setup
error was assumed present in this MLC-tracked scenario.
Treatment plans based on the tracking ITVs were generated
using the AutoBeam in-house inverse planning system [12] and
consisted of a single anticlockwise volumetric modulated arc ther-
apy (VMAT) arc from 175 to 185, with control points spaced at 5
intervals, for delivery using a 6-MV flattened beam. Collimator
angle was 2 in all cases to spread out any interleaf leakage. This
resulted in MLC leaf motion perpendicular to the direction of
tumour motion. The apertures conformed to the beam’s eye view
of the tracking ITV, with zero penumbra margin, except superiorly
and inferiorly, where the penumbra margin was 4 mm. The control
point weights were iteratively adjusted by the inverse planning
process to additionally conform the treatment plans to the tracking
ITV [12]. The dose prescription was 55 Gy in 5 fractions to 95% of
the tracking ITV. This planning approach resulted in a prescription
isodose which was between 60% and 90% of the maximum dose in
all cases, and typically around 70%.
A software application was produced to calculate the effect of
the respiration on the treatment plan. Breathing motion was then
taken to be purely in the superior–inferior direction:
z ¼ A 2A sin6½pt = T; ð1Þ
where z was positive towards the head of the patient, the peak–
peak amplitude 2A was taken to be between 10 mm and 30 mm
and the time period of motion, T, was taken to be between 2 s
and 4 s [13]. Although this model was simple, its advantage was
that it enabled a wide range of motions to be conveniently simu-
lated. Tracking motion was taken to be of the form:
z ¼ A 2A sin6½pðt  hÞ = T; ð2Þ
where the latency h was varied from 0 ms to 500 ms in 50 ms inter-
vals. The same motion equations were also investigated with an
exponent of two instead of six [13], for comparison purposes. The
beam isocentre position relative to the centre of the GTV resulting
from tracking with a system latency, was then taken as the differ-
ence between Eqs. (1) and (2). To give an indication of how the
model related to real clinical breathing traces, the superior–inferior
component of the high-frequency motion trace described by Sawant
et al. [8], in turn based on the work of Suh et al. [14], was also used
in the same way.
The difference between the beam isocentre and the centre of
the GTV was used to construct a probability density function
(PDF) of the proportion of time spent by the isocentre at each posi-
tion, in integral numbers of mm, relative to the centre of the GTV.In order to evaluate the resulting dose distribution, the entire
VMAT plan was computed on a dose grid of 2 mm  2 mm  2 mm
in Pinnacle3 (Philips Radiation Oncology Systems, Madison, WI) on
isocentres positioned at 1-mm intervals from 20 mm superior to
the centre of the GTV to 20 mm inferior to the centre of the GTV.
The ±20 mm range was necessary to accommodate the worst case
scenario of the beam aperture being in antiphase to the GTV. The
component dose distributions were then superposed according to
the value of the PDF at each position. The result represented the
dose distribution that would be obtained after a number of deliv-
eries of the VMAT plan (Fig. 1). The process was repeated for all
of the plans based on each tracking ITV. The value of D95% for the
GTV and V13Gy for normal lung was recorded for all latencies and
tracking ITVs.
The calculations were repeated with z = 0 in Eq. (2) to indicate
the outcome if treatment were performed without tracking using
an isocentre located midway between the motion extrema. This
was for purposes of comparison only, as the breath-hold CT scan
used in this study was not strictly appropriate to this free-
breathing situation.Verification measurements
The treatment plans for zero tracking ITV margin were recalcu-
lated on an artificial dataset representing a Delta4 phantom
(ScandiDos, Uppsala, Sweden) [15], using a dose grid of resolution
2 mm  2 mm  2 mm. The plans were then delivered using a
Synergy accelerator with Agility MLC (Elekta AB, Stockholm,
Sweden) [16] and the dose was measured using the Delta4 phan-
tom. The Delta4 phantom was positioned by means of the in-
room lasers on a programmable motion platform [17]
(Supplementary Fig. S1) and the platform set to move in the supe-
rior–inferior direction with the motion described by Eq. (1). The
accuracy of setup was estimated to be ±1 mm. The motion platform
reported its position every 25 ms to an in-house tracking pro-
gramme, which calculated the desired MLC leaf positions and
requested the accelerator to move the MLC leaves to that position
[6]. Various latencies were introduced into the tracking software,
so that the total system latency varied from 0 ms to 500 ms in
100 ms intervals. The system latency was 69 ms [6], so to achieve
a latency of 0 ms, a linear regression motion prediction method
was used, resulting in a residual latency of less than 10 ms [10].
For all the other latencies, motion prediction was turned off. The
value of D95% for the GTV was obtained from the dose–volume his-
togram reconstructed in the phantom environment by the Delta4
software from the measurements and supplied depth dose curves.
It was not possible to evaluate lung dose in the phantom study.Results
With zero tracking ITV margin and with no latency, D95% was
55 Gy as prescribed (Fig. 2a). As the latency increased, the D95%
dropped. It was postulated that a drop in D95% of 2% to 53.9 Gy
was acceptable, and for an amplitude of 10 mm and a period of
4s, this occurred at a latency of around 150 ms. In general, larger
GTVs were less affected by latency than smaller GTVs, with the
range of D95% values being around 3 Gy at 500 ms latency. If a
tracking ITV margin was used, the prescription of D95% = 55 Gy
was given to the tracking ITV, so that the GTV D95% was somewhat
higher than 55 Gy due to the non-uniformity of ITV dose in this
type of treatment plan. Because of the tracking ITV margin, the
GTV coverage was more resilient to motion, so that the drop in
GTV D95% to 53.9 Gy did not occur until 350 ms (1-mm margin)
or 450 ms (2-mm) margin. Corresponding results for sin2(t) motion
as opposed to sin6(t) motion were also demonstrated (Fig. 2b).
Fig. 1. Tracking model for sin6(t) motion with 500 ms latency and 2-mm tracking
ITV margin. (a) Motion traces, showing tumour position (ACTUAL), beam position
(TRACKED) and difference between the two (ERROR), (b) probability density
function of beam position in relation to the tumour, (c) coronal dose distribution for
the VMAT treatment plan of a single patient based on an isocentre at the centre of
the gross tumour volume (purple region), but with the isocentres of the complete
set of dose components shown (black circles), (d) dose–volume histograms. Note
that with this latency and margin, neither the tracking ITV nor the GTV receive the
prescribed dose of 55 Gy to 95%.
Fig. 2. Mean gross tumour volume (GTV) coverage for the five patients as a function
of internal target margin and tracking system latency for amplitude 10 mm and
period 4s. (a) sin6(t) motion, (b) sin2(t) motion. The threshold of 2% dose reduction
from 55 Gy is shown as a dotted line. The inset shows the probability density
function for 500 ms latency in each case.
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margin was increased from 0 mm to 5 mm. The irradiated volume
of lung was only weakly dependent on the latency and the form of
breathing trace, i.e. sin6(t) motion or sin2(t) motion.In general, system latency had a larger impact on GTV D95% for
larger amplitudes and shorter periods of breathing motion (Fig. 3).
This was to be expected as the GTV moved by a larger distance in a
given time for these conditions. The clinically recorded motion tra-
jectory produced similar results to the Lujan model with an ampli-
tude of 5 mm and a period of 4 s (Fig. 3).
If treatment was performed without tracking, GTV D95% was
36.7 Gy with sin6(t) motion and zero ITV margin, rising to
55.8 Gy with a 5-mm margin. Lung V13Gy rose from 3.6% to 5.5%
over the same range of margins.
The impact of system latency on the measured GTV D95% in the
phantomwas very similar to that predicted by the model (Fig. 4). A
drop in D95% of 2% was observed at around 100 ms.Discussion
The simulation study showed clearly that a tracking system
latency of up to 150 ms had a negligible impact on the accuracy
of conformal VMAT treatment plan delivery for larger-than-
average tumour motion, while in the phantom study, a value of
approximately 100 ms was obtained. The simulation took account
of the inhomogeneous environment around the GTV, whereas the
phantom study used a homogeneous phantom, so the simulation
was likely to better represent the inhomogeneous situation present
in a lung SABR treatment. On the other hand, the delivery study
included practical effects such as MLC refitting.
For the Agility MLC used in this study, the MLC adjustment
latency was in the order of 60–70 ms, depending on the motion
trajectory, so a further latency of up to 80 ms in the motion
Fig. 3. Mean gross tumour volume (GTV) coverage for the five patients as a function
of amplitude, period and tracking system latency for 0 mm tracking ITV margin. All
curves are for sin6(t) motion, with the exception of that marked Suh et al. (closely
following that of 5 mm 4 s), which uses a recorded breathing trace from the
literature. The threshold of 2% dose reduction from 55 Gy is shown as a dotted line.
The inset shows the probability density function for 500 ms latency for the recorded
breathing trace (Suh et al.).
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In practice, the likely scenario was that motion prediction would
be used to obtain as low a residual latency as possible, but that if
the patient were to breathe arhythmically at some point during
the treatment, the prediction could be automatically switched off
and/or retrained. With a system latency of less than 150 ms, this
would not be problematic.
The results were slightly dependent on the form of the motion
trace used for the motion model. The sin6(t) model spent a rela-
tively long period of time at the exhale position, so there was time
for the tracking beam to catch up, even with a significant latency.
However, the results for sin2(t) were not very dissimilar. In this
case, although less time was spent at the exhale position, the veloc-
ity between inhale and exhale was lower, so the tracking system
was not so challenged in this time interval. The results for an expo-
nent of four, as is often used with the Lujan model [13], were
expected to lie between these two cases. The motion model used
in this study also assumed superior–inferior motion in the interest
of making the calculations tractable. This assumption was unlikelyFig. 4. Mean (±1 SD) gross tumour volume (GTV) coverage, relative to dose
measured without motion and normalised to 55 Gy, for the five patients as
measured by the Delta4 phantom, as a function of tracking system latency. Shown
on the same scale as Fig. 2. The inset shows the planned dose distribution (greyscale
and isodoses from 10% to 100% of isocentre dose in 10% intervals) and measured
dose distribution (squares coloured according to scale included) for one of the
patients on the Delta4 with 500 ms latency.to have a significant impact on the results. In principle, there could
also have been some interplay between the breathing motion and
the treatment delivery, which this study neglected by summing the
entire treatment plan at each superior–inferior offset, thereby giv-
ing the results expected after delivery of a number of treatment
fractions. The good agreement of GTV dose in the phantom study,
which consists of delivering only one fraction of treatment, with
the simulation, supported this view.
The patient was assumed in this study to be a rigid body,
whereas in reality it deforms between breathing phases. As the
superior–inferior variation in patient contour was small over the
±10 mm of motion considered in this study, it was not thought that
this significantly affected the results, but it was a source of uncer-
tainty. The effect was likely to have less of an impact at shorter
latencies, where the offset between beam aperture and GTV was
small. In addition, the calculation of lung dose was limited in this
study due to the rigid body model used. In a tracking treatment,
the target and the beam oscillate superiorly and inferiorly, so that
the dose deposition is spread out over the normal lung, influencing
the irradiated volume. However, in this study, the tracked target
was represented as stationary, so that this effect was not taken into
account. One could estimate this effect by calculating lung dose
based on the individual breathing phases. The errors were likely
to be greater further from the GTV, as the lung tissue around the
GTV deforms with the GTV itself during respiration, so that the cur-
rently simplified model was more relevant. Possible differential
motion between the GTV and critical structures was also not taken
into account by the rigid model.
The use of conformal VMAT was robust for this type of treat-
ment planning, as it prevented the optimiser from attempting to
boost the dose to the low density lung tissue surrounding the
GTV, and was sufficient to provide a high-quality treatment plan.
The implications for MLC tracking were twofold: firstly, the MLC
fit to the PTV was generally optimum with the direction of leaf
motion transaxially oriented, which was challenging when track-
ing superior–inferior motion, and secondly, it may have lessened
the impact of any latency effects as only the periphery of the track-
ing ITV was affected by spatial mismatch between the GTV position
and the aperture position. Other studies have investigated the use
of VMAT with more complex modulation for tumour tracking
[2,18] and reported on the impact of collimator orientation [18].
The simulation study assumed that the MLC leaves were able to
follow the perpendicular motion accurately, with the specified
latency, so that with zero latency, the leaves fitted the ITV accu-
rately at all times. For this reason, the results of the study were
expected to be applicable to other tracking methods such as couch
tracking or tracking with a gimballed head. In contrast, the phan-
tom study demonstrated tracking of motion perpendicular to the
MLC leaves, where the leaves must be continually refitted to the
moving target. This refitting of leaves was included in the MLC
adjustment latency, which in turn formed part of the system
latency.
The results were comparable to those of other studies. For
example Sawkey et al. [5] calculated using realistic breathing
traces that for a latency of 50 ms, a tracking ITV margin of
1.2 mm (range 0.6–2.6 mm) was needed, and that for a latency of
200 ms, a tracking ITV margin of 4.1 mm (range 2.3–7.6 mm) was
needed. This was based on a requirement that the reference dose
should be greater than 95%, which, when translated into individual
directions, required that the reference point should be irradiated
for 0.975 of the time. The present study predicted that smaller
margins were adequate, probably due to the more extensive dosi-
metric calculation, in which the beam penumbra and inhomo-
geneities around the GTV were taken into account.
Similarly, Falk et al. [18] reported on delivery of RapidArc
(Varian, Palo Alto, CA) for conventionally fractionated lung plans,
J.L. Bedford et al. / Radiotherapy and Oncology 117 (2015) 491–495 495using an MLC tracking system with a latency of 160 ms. They used
a margin estimation method in conjunction with measurements in
a Delta4 phantom to calculate that for a peak–peak amplitude of
20 mm, dynamic tumour tracking was expected to facilitate a
reduction in PTV margin of 2–4 mm. Depuydt et al. [19] also inves-
tigated the potential for margin reduction based on the results of
clinical SABR lung treatments using a gimballed linear accelerator.
They estimated that GTV-PTV margins could potentially be
reduced from 5 mm to 3 mm, but cautioned against excessive
reduction in margins in view of uncertainty in geometric definition
and biological distribution of the GTV, notably in microscopic dis-
ease extension.
This biological uncertainty also formed a background to the pre-
sent study. In addition, there were limitations in the study itself,
for example that internal motion could be modelled by a rigid
translation of the patient. However, from the simulation and mea-
surements, it was concluded that MLC tracking of conformal VMAT
could be effectively accomplished in the absence of an internal tar-
get margin for substantial breathing motion (4 s period and 20 mm
peak–peak amplitude) so long as the system latency was less than
150 ms. Latencies of less than this resulted in a drop in GTV D95% of
less than 2%. Longer latencies of up to 450 ms could be effectively
mitigated by the use of a 2-mm tracking ITV margin.
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